| Ms Alyse C Bynum, PT | |
|
31 Hall Dr, Amherst Medical Center, Amherst, MA 01002-2751 | |
| (413) 256-8561 | |
| (413) 256-4490 |
| Full Name | Ms Alyse C Bynum |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 31 Hall Dr, Amherst, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386628899 | NPI | - | NPPES |
| 2358775 | Other | MA | AETNA US/HEALTHCARE |
| OT0006 | Other | MA | BLUE CROSS BLUE SHIELD |
| 0331881 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 3101 (Massachusetts) | Primary |
| Provider Name | Valley Medical Group Pc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1558406512 PECOS PAC ID: 2365348851 Enrollment ID: O20040928000742 |
News Archive
Following advice from the Joint Committee on Vaccination and Immunisation (JCVI) the current universal BCG vaccination programme delivered through schools will be replaced with an improved programme of targeted vaccination for those individuals who are at greatest risk.
A new study discusses the application of a novel deconvolution model AImmune to predict moderate and severe cases of COVID-19.
Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).
Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Alyse C Bynum, PT Po Box 5700, Belfast, ME 04915-5700 Ph: (866) 431-4077 | Ms Alyse C Bynum, PT 31 Hall Dr, Amherst Medical Center, Amherst, MA 01002-2751 Ph: (413) 256-8561 |
News Archive
Following advice from the Joint Committee on Vaccination and Immunisation (JCVI) the current universal BCG vaccination programme delivered through schools will be replaced with an improved programme of targeted vaccination for those individuals who are at greatest risk.
A new study discusses the application of a novel deconvolution model AImmune to predict moderate and severe cases of COVID-19.
Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).
Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.
› Verified 8 days ago
Naomi Dratfield, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 39 Autumn Lane, Amherst, MA 01002 Phone: 413-256-4784 | |
Ms. Mia Lovechio, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 132 Northampton Rd, Amherst, MA 01002 Phone: 413-330-3117 | |
Dianne Iannitelli, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 31 Hall Dr, Valley Medical Group, Pc-amherst Medical Center, Amherst, MA 01002 Phone: 413-256-8561 Fax: 866-644-0869 | |
Mary Lynn Jacobs, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 University Dr, Suite A-6, Amherst, MA 01002 Phone: 413-366-5703 Fax: 413-992-2019 | |
Katarina Hallonblad, M.S., OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 16 S Sunset Ave, Amherst, MA 01002 Phone: 413-522-4735 Fax: 413-702-0000 | |
Gary F Bivona, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 51 Pine St, Amherst, MA 01002 Phone: 413-695-3483 |